Emicizumab

艾美赛珠单抗

Report date: 2026/03/04 20:01:44
First In Class

Base Information

Drug NameEmicizumab
Drug Alias NameEmicizumab-kxwh依米赛珠单抗emicizumabum艾米希组单抗舒友立乐 +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Factor IXaAnti-Factor X
TargetsCoagulation factor XCoagulation factor IX
Therapy Area/IndicationsHemorrhagevon Willebrand Disease, Type 3Hemophilia A
Global Approved IndicationsHemophilia A
Approved Indications in ChinaHemophilia A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/11/16
Country/TerritoryBelgiumCanadaPanama +[40] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesChugai Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBleeding and Clotting Disorders InstituteChugai Pharmaceutical Co LtdGwt-Tud Gmbh +[9] 
Inactive CompaniesUniversity Of WashingtonTulane UniversityNanjing Zhengda Tianqing Pharmaceutical Co Ltd
Active IndicationsHemorrhagevon Willebrand Disease, Type 3Hemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeB02BX06
Related LinksWikipediaDrugBankKEGG